The first-ever legally approved cannabis-based drug became available to patients in the United States recently. It's a true game-changer. But it may find some stiff competition from products that aren't being reviewed by the FDA.
It's time to add two more cannabis names to the NYSE scoreboard. This week, two of the big five Canadian producers join their fellow colleagues in migrating to a massive U.S. exchange - a trend our Executive Director isn't expecting to stop anytime soon. But that doesn't mean investors should rush out and snap up shares. Instead, he's got his eyes on a few other up-and-comers that offer even greater potential.
The cannabis market is starting to soar. The United States is a vast market opportunity, with market projections growing from an estimated $8.5 billion last year to $23.4 billion in 2022 if only a few additional states legalize recreational use. And we're talking about as much as $50 billion if most states follow the trend.
The last month of action in Canadian cannabis stocks has many investors wondering: "Have I missed the boat?" With the sort of life-changing gains we've seen in the cannabis space in 2018, it's natural to ask if the boat has sailed, at least for the foreseeable future. The good news is, the biggest wave in cannabis stock gains hasn't shown up yet (not even in Canada). And today, we're going to show you how to claim your fair share of the profits.